Tissue levels of matrix metalloproteinases MMP-2 and MMP-9 are related to the overall survival of patients with gastric carcinoma

British Journal of Cancer

Volumn 74, Issue 3, 1996, Pages 413-417

  Sier, C F M ^a   Kubben, F J G M ^a   Ganesh, S ^a   Heerding, M M ^a   Griffioen, G ^a   Hanemaaijer, R ^b   Van Krieken, J H J M ^a   Lamers, C B H W ^a   Verspaget, H W ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b TNO   (Netherlands)

Author keywords

Gastric carcinoma; Gelatinases; Matrix metalloproteinase; Quantitative zymography

Indexed keywords

GELATINASE; GELATINASE B; PROTEINASE;

ADULT; AGED; ARTICLE; CANCER CLASSIFICATION; CANCER INVASION; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MALE; METASTASIS; PRIORITY JOURNAL; PROGNOSIS; STOMACH CARCINOMA; STOMACH MUCOSA;

EID: 0030016640     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1996.374     Document Type: Article

References (28)

1. BERGMANN U, MICHAELI J, OBERHOFF R, KNAUPBR V, BECKMANN R AND TSCHESCHE H. (1989). Enzyme linked immunosorbent assays (ELISA) for the quantitative determination of human leukocyte collagenase and gelatinase. J. Clin. Chem. Clin. Biochem., 27, 351 359.
2. COX DR. (1972). Regression models and life-tables. J. R. Stat. Soc. (B), 34, 187-220.
3. DUFFY MJ. (1992). The role of proteolytic enzymes in cancer invasion and metastasis. Clin. Exp. Metast., 10, 145-155.
4. DUFFY MJ, O'GRADY P, DEVANEY D, O'SIORAIN L, FENNELLY JJ AND LIJNEN HR. (1988). Tissue-type plasminogen activator, a new prognostic marker in breast cancer. Cancer Res., 48, 1348 1349.
5. DUFFY MJ, BLÄSER J, DUGGAN C, MCDERMOTT E, O'HIGGENS N, FENNELLY JJ AND TSCHESCHE H. (1995). Assay of metalloproteases types 8 and 9 by ELISA in human breast cancer. Br. J. Cancer, 71, 1025 1028.
6. EMMERT-BUCK MR, ROTH MJ, ZHUANG Z, CAMPO E, ROZHIN J, SLOANK BF, LIOTTA LA AND STETLER-STEVENSON WG. (1994). Increased gelatinase A (MMP-2) and cathepsin B activity in invasive tumor regions of human colon cancer samples. Am. J. Pathol., 145, 1285 1290.
7. GANESH S, SIER CFM, GRIFFIOEN G, VLOEDGRAVEN HJM, DE BOER A, WELVAART K, VAN DE VELDE CJH, VAN KRIEKEN JHJM, VERHEIJEN JH, LAMERS CBHW AND VERSPAGET HW. (1994a). Prognostic relevance of plasminogen activators and their inhibitors in colorectal cancer. Cancer Res., 54, 4065 4071.
8. GANESH S, SIER CFM, HEERDING MM, GRIFFIOEN G, LAMERS CBHW AND VERSPAGET HW. (1994b). Urokinase receptor and colorectal cancer survival. Lancet, 344, 583 584.
9. GANESH S, SIER CFM, HEERDING MM, VAN KRIEKEN JHJM, GRIFFIOEN G, WELVAART K, VAN DE VELDE CJH, VERHEIJEN JH, LAMERS CBHW AND VERSPAGET HW. (1996). Prognostic value of the plasminogen activation system in patients with gastric cancer. Cancer, (in press).
10. GRIGIONI WF, D'ERRICO A, FORTUNATO C, FIORENTINO M, MANCINI AM, STETLER-STEVENSON WG, SOBEL ME, LIOTTA LA, ONISTO M AND GARBISA S. (1994). Prognosis of gastric carcinoma revealed by interactions between tumor cells and basement membrane. Mod. Pathol., 7, 220-225.
11. HANEMAAIJER R, KOOLWIJK P, LE CLERCQ L, DE VREE WJA AND VAN HINSBERGH VWM. (1993). Regulation of matrix metalloproteinase expression in human vein and microvascular endothelial cells. Biochem. J., 296, 803-809.
12. HASUI Y, MARUTSUKA K, SUZUMIYA J, KITADA S, OSADA Y AND SUMIYOSHI A. (1992). The content of urokinase-type plasminogen activator antigen as a prognostic factor in urinary bladder cancer. Int. J. Cancer, 50, 871-873.
13. JÄNICKE F, SCHMITT M AND GRAEFF H. (1991). Clinical relevance of the urokinase-type and tissue-type plasminogen activators and of their type 1 inhibitor in breast cancer. Semin. Thromb. Hemost., 17, 303-312.
14. KAPLAN EL AND MEIER P. (1958). Nonparametric estimation from incomplete observations. J. Am. Stat. Assoc., 53, 457-481.
15. KIMURA T, IWAGAKI H, FUCHIMOTO S, HIZUTA A AND ORITA K. (1993). Relationship between type 1 collagenase activity, invasiveness and metastatic potential in colorectal carcinoma. Cancer J., 6, 77-80.
16. KLEINER DE AND STETLER-STEVENSON WG. (1994). Quantitative zymography: detection of picogram quantities of gelatinases. Anal. Biochem., 218, 325-329.
17. LOWRY OH, ROSEBROUGH NJ, FARR AL AND RANDALL RJ. (1951). Protein measurement with the folin phenol reagent. J. Biol. Chem., 193, 265-275.
18. MCDONNELL S, NAVRE M, COFFEY RJ AND MATRISIAN LM. (1991). Expression and localization of the matrix metalloproteinase Pump-1 (MMP-7) in human gastric and colon carcinomas. Mol. Carcinogen., 4, 527-533.
19. MATRISIAN LM. (1992). The matrix-degrading metalloproteinases. BioEssays, 14, 455-463.
20. NAITO K, KANBAYASHI N, NAKAJIMA S, MURAJ T, ARAKAWA K, NISHIMURA S AND OKUYAMA A. (1994). Inhibition of growth of human tumor cells in nude mice by a metalloproteinase inhibitor. Int. J. Cancer, 58, 730-735.
21. NEKARDA H, SCHMITT M, ULM K, WENNINGER A, VOGELSANG H, BECKER K, RODER JD, FINK U AND SIEWERT JR (1994). Prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in completely resected gastric cancer. Cancer Res., 54, 2900-2907.
22. PEDERSEN H, BRUNNER N, FRANCIS D, ØSTERLIND K. RØNNE E, HANSEN HH, DANØ K AND GRØNDAHL-HANSEN J. (1994). Prognostic impact of urokinase, urokinase receptor, and type 1 plasminogen activator inhibitor in squamous and large cell lung cancer tissue. Cancer Res., 54, 4671-4675.
23. POULSOM R, PIGNATELLI M, STETLER-STEVENSON WG, LIOTTA LA, WRIGHT PA, JEFFERY RE, LONGCROFT JM, ROGERS L AND STAMP GWH. (1992). Stromal expression of 72 kda Type IV collagenase (MMP-2) and TIMP-2 mRNAs in colorectal neoplasias. Am. J. Pathol., 141, 389-396.
24. SIER CFM, VERSPAGET HW, GRIFFIOEN G, VERHEIJEN JH, QUAX PHA, DOOIJEWAARD G, DE BRUIN PAF AND LAMERS CBHW. (1991). Imbalance of plasminogen activators and their inhibitors in human colorectal neoplasia. Implication of urokinase in colorectal carcinogenesis. Gastroenterology, 101, 1522-1528.
25. WANG X, FU X, BROWN PD, CRIMMIN MJ AND HOFFMAN RM. (1994). Matrix metalloproteinase inhibitor BB-94 (Batimastat) inhibits human colon tumor growth and spread in a patient-like orthotopic model in nude mice. Cancer Res., 4726-4728.
26. YAMAGATA S, YOSHII Y, SUH JG, TANAKA R AND SHIMIZU S. (1991). Occurrence of an active form of gelatinase in human gastric and colorectal carcinoma tissue. Cancer Lett., 59, 51-55.
27. ZUCKER S, LYSIK RM, ZARRABI MH AND MOLL U. (1993). Mr 92,000 collagenase is increased in plasma of patients with colon cancer and breast cancer. Cancer Res., 53, 140-146.
28. ZUCKER S, MANCUSO P, DIMASSIMO B, LYSIK RM, CONNER C AND WU CL. (1994). Comparison of techniques for measurement of gelatinases/type IV collagenases: enzyme-linked immunoassays versus substrate degradation assays. Clin. Exp. Metast., 12, 13-23.